Farther Finance Advisors’s Lexaria Bioscience LEXX Stock Holding History

Farther Finance Advisors’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96	Hold	11	–	–	﹤0.01%	5798
2026 Q1	$144	Hold	11	–	–	﹤0.01%	5473
2025 Q4	$102	Hold	11	–	–	﹤0.01%	5296
2025 Q3	$158	Hold	11	–	–	﹤0.01%	4773
2025 Q2	$144	Hold	11	–	–	﹤0.01%	4258
2025 Q1	$272	Hold	11	–	–	﹤0.01%	3893
2024 Q4	$349	Hold	11	–	–	﹤0.01%	3519
2024 Q3	$506	Hold	11	–	–	﹤0.01%	3425
2024 Q2	$458	Hold	11	–	–	﹤0.01%	3302
2024 Q1	$568	Hold	11	–	–	﹤0.01%	2981
2023 Q4	$208	Hold	11	–	–	﹤0.01%	3218
2023 Q3	$166	Hold	11	–	–	﹤0.01%	2489
2023 Q2	$121	Hold	11	–	–	﹤0.01%	2417
2023 Q1	$452	Buy	+11	New	+$470	﹤0.01%	2029

Other funds holding LEXX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

CBT

Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Farther Finance Advisors's LEXX Position: Q2 2026 in Review

Farther Finance Advisors held its Lexaria Bioscience (LEXX) position steady in Q2 2026 at 11 shares worth $96. The position accounts for ﹤0.01% of the portfolio, ranked #5798.

Farther Finance Advisors first reported a position in LEXX in Q1 2023 and has held it in 14 quarters since. The position peaked at $568 in Q1 2024. 6 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

Farther Finance Advisors held 11 shares of Lexaria Bioscience worth $96 as of Q2 2026.
Farther Finance Advisors left its Lexaria Bioscience share count unchanged in Q2 2026.
Lexaria Bioscience made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5798 holding.
Farther Finance Advisors first reported a position in Lexaria Bioscience in Q1 2023 and has held it in 14 quarters since.
Farther Finance Advisors's Lexaria Bioscience position peaked at $568 in Q1 2024.
6 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.